Developer docs
API playgroundTry for free, no card

Search company profiles

Synlogic

Full company profile

uuid0002h6g

Namestring
Synlogic
Legal namestring
Synlogic, Inc.
Websiteurl
synlogictx.com
Company typeenum
Public
Founded yearint
2014
Descriptiontext

Synlogic, Inc. is a clinical-stage biotechnology company founded in 2014 by MIT researchers James Collins, PhD, and Tim Lu, MD, PhD, to develop Synthetic Biotics — a class of oral, GI-restricted medicines produced through precision genetic engineering of well-characterized probiotic bacteria. The company's proprietary platform combines molecular biology, microbial engineering, and physiology, supported by a library of synthetic biology components, metabolic gene circuitry, and regulatory genetic switches that enable engineered probiotics to consume or modify disease-specific metabolites within the gastrointestinal tract. The clinical pipeline includes labafenogene marselecobac (SYNB1934) for phenylketonuria under the Synpheny program, SYNB1353 for homocystinuria, SYNB8802 for enteric hyperoxaluria, SYNB2081 for gout, a preclinical cystinuria program, and an inflammatory bowel disease program developed in collaboration with Roche.

Synlogic is pre-revenue with no approved products, and operates as a publicly traded company on NASDAQ under ticker SYBX, headquartered in Cambridge, MA with a headcount of roughly 51–100 employees. The company's business model is structured around advancing drug candidates through clinical development toward regulatory approval, with the long-term monetization path based either on direct commercialization of approved biotherapeutics targeting rare metabolic diseases or on out-licensing rights to larger commercial partners. As of October 2023, the company completed a $21.0 million underwritten public offering intended to extend operating runway into the first half of 2025; operations have historically been funded through a mix of venture capital, public equity offerings, and strategic partnerships including a Roche IBD collaboration and an early-stage synthetic biology partnership with Ginkgo Bioworks.

Synlogic serves patients with rare metabolic diseases — including phenylketonuria, homocystinuria, enteric hyperoxaluria, gout, and cystinuria — where existing treatment options are limited by safety, efficacy, or tolerability concerns. The go-to-market approach, contingent on future approval, would rely on specialty rare-disease commercialization channels, healthcare provider engagement in metabolic disease centers, and patient advocacy partnerships. The discontinuation of the Synpheny-3 Phase 3 study in phenylketonuria materially reshaped the company's near-term trajectory and forced a strategic refocus toward earlier-stage pipeline assets and partnership-driven development.

Short descriptiontext

Synlogic is a clinical-stage biotechnology company developing Synthetic Biotics — orally administered, GI-restricted engineered probiotic medicines designed to consume or modify disease-specific metabolites. It targets patients with rare metabolic diseases including phenylketonuria, homocystinuria, enteric hyperoxaluria, gout, and cystinuria.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
synthetic biotic medicines, rare metabolic therapeutics, engineered probiotic drugs, oral biotherapeutic candidates, clinical-stage biopharmaceuticals
Industry2 codes
PRIMARYHLAAAFAD
Engineered Microbial Therapeutics (synthetic biology, gene circuits)
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biotherapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Biopharmaceutical Development
TypeLicensing Royalties
Description

As a clinical-stage biotechnology company, Synlogic is focused on developing and commercializing its pipeline of Synthetic Biotics for rare metabolic diseases. The company is pre-revenue with no approved products yet, and is funded through public offerings and partnerships to advance clinical development toward regulatory approval.

synlogictx.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Others, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Synpheny
Description

Brand name associated with Synlogic's phenylketonuria (PKU) treatment program and the drug candidate labafenogene marselecobac (SYNB1934).

synlogictx.com
Core offering1 text field

Synlogic develops Synthetic Biotics, a class of orally administered, GI-restricted biotherapeutic drug candidates created by precision genetic engineering of well-characterized probiotics. These drug candidates are designed to consume or modify disease-specific metabolites in the gastrointestinal tract to treat rare metabolic diseases including phenylketonuria (PKU), classical homocystinuria (HCU), enteric hyperoxaluria, gout, and cystinuria. The company operates a clinical-stage pipeline and is pre-revenue, advancing candidates through clinical trials toward regulatory approval.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • SYNB1934 demonstrated proof of concept in clinical studies for PKU treatment
+2 more records
Product overview1 text field

Synlogic is a clinical-stage biotechnology company developing Synthetic Biotics, a platform of living therapeutics created through precision genetic engineering of well-characterized probiotics. The company's portfolio includes multiple drug candidates: Labafenogene marselecobac (SYNB1934/Synpheny) for phenylketonuria (PKU), SYNB1353 for classical homocystinuria (HCU), SYNB8802 for enteric hyperoxaluria, SYNB2081 for gout, an undisclosed program for cystinuria, and an IBD program in collaboration with Roche. All candidates are designed as oral, GI-restricted medicines that consume or modify disease-specific metabolites.

Product and service6 records
1Labafenogene marselecobac (SYNB1934) / Synpheny
CategoryBiotherapeutic drug candidate
Description

An orally administered, GI-restricted Synthetic Biotic drug candidate designed to consume phenylalanine in the gastrointestinal tract, intended as a biotherapeutic for patients with phenylketonuria (PKU), an inherited metabolic disease where current treatment options are limited.

2SYNB1353
CategoryBiotherapeutic drug candidate
Description

A novel orally-administered, non-systemically absorbed Synthetic Biotic drug candidate designed to consume methionine in the gastrointestinal tract, thereby lowering homocysteine levels in patients with classical homocystinuria (HCU).

3SYNB8802
CategoryBiotherapeutic drug candidate
Description

A Synthetic Biotic drug candidate designed to consume dietary oxalate throughout the GI tract, being studied as a potential treatment for enteric hyperoxaluria, a chronic progressive disease characterized by high levels of urinary oxalate leading to recurrent kidney stones, kidney damage, and potential CKD/ESRD.

4SYNB2081
CategoryBiotherapeutic drug candidate
Description

A Synthetic Biotic drug candidate designed to lower uric acid as a potential treatment of gout, a complex form of inflammatory arthritis occurring when extra uric acid forms crystals in joints, causing intense pain, inflammation, and limited range of motion.

5Undisclosed Cystinuria Program
CategoryBiotherapeutic drug candidate
Description

An early-stage Synthetic Biotic drug candidate program exploring the potential to reduce cystine in urine as a treatment for cystinuria, a genetic disease in which kidney stones consisting of cystine form and may recur or become lodged in the kidneys, ureters, or bladder.

6IBD Program (Roche Collaboration)
CategoryBiotherapeutic drug candidate
Description

A research-stage Synthetic Biotic program under collaboration with Roche focused on the discovery of a novel oral biotherapeutic for the treatment of inflammatory bowel disease (IBD).

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-06-01
Description

In June 2021, Synlogic began a research collaboration with Roche focused on the discovery of a novel Synthetic Biotic for the treatment of inflammatory bowel disease (IBD). The partnership leverages Synlogic's synthetic biology expertise in combination with Roche's resources for drug discovery.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Synlogic partnered with Ginkgo Bioworks to develop additional preclinical assets, combining Synlogic's Synthetic Biotics approach with Ginkgo's Codebase and Foundry services. This partnership yielded SYNB1353 (for HCU) and SYNB2081 (for gout), the company's second drug candidate developed through this partnership.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Clinical-stage gene therapy company with a PKU program (and other rare metabolic disease candidates). Comparable as a competing modality (gene therapy) targeting the same rare metabolic indications in Synlogic's pipeline.

TypeEmerging player
Description

Emerging engineered-microbiome company using synthetic biology to program resident bacteria (and phages) for precision therapeutic action. Comparable as a synthetic-biology-driven engineered microbe platform, though earlier-stage and more delivery-modality focused.

TypeDirect peer
Description

Clinical-stage microbiome therapeutics company developing defined bacterial consortia for serious diseases (including SER-109 for recurrent C. difficile infection). Closely comparable to Synlogic in modality, stage, and reliance on regulatory designations and capital markets.

4Federation Bio
TypeEmerging player
Description

Synthetic biology platform engineering defined and synthetic microbial communities for therapeutic use. Comparable through use of synthetic biology to engineer consortia of microbes to modulate disease-relevant metabolites in the GI tract.

TypeBroad incumbent
Description

Established rare-disease leader with approved PKU treatments (Palynziq, pegvaliase). Not a microbiome peer, but a broad incumbent defining the commercial market and competitive landscape that Synlogic's discontinued PKU program would have entered.

6Novome Biotechnologies
TypeDirect peer
Description

Engineered microbial therapeutics company using genetically engineered gut bacteria to consume disease-driving metabolites (initial focus on hyperoxaluria). Highly comparable platform concept — engineered probiotics consuming metabolites — directly overlaps with SYNB8802's indication.

TypeOthers
Description

Synthetic biology platform company that is both a Synlogic collaboration partner (producing SYNB1353 and SYNB2081) and an adjacent infrastructure provider of engineered organism development services. Not a therapeutic competitor, but a strategic partner and ecosystem enabler.

84D Pharma
TypeDirect peer
Description

Clinical-stage microbiome therapeutics company with a pipeline of single-strain Live Biotherapeutic Products (LBPs) for cancer, respiratory, and gastrointestinal indications. Directly comparable modality and stage to Synlogic's Synthetic Biotics platform.

TypeDirect peer
Description

Develops defined bacterial consortia and live biotherapeutics for immune-mediated diseases. Direct peer given shared focus on orally administered, GI-restricted bacterial therapeutics and similar mechanism-of-action leveraging the microbiome.

TypeDirect peer
Description

Clinical-stage company developing orally delivered microbial therapeutics for inflammatory diseases and oncology. Direct peer given shared GI-restricted single-strain therapeutic concept and rare/serious disease focus.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds12 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Synlogic

Biotherapeuticssynlogictx.com

Synlogic is a clinical-stage biotechnology company developing Synthetic Biotics — orally administered, GI-restricted engineered probiotic medicines designed to consume or modify disease-specific metabolites. It targets patients with rare metabolic diseases including phenylketonuria, homocystinuria, enteric hyperoxaluria, gout, and cystinuria.

What Synlogic does

Synlogic, Inc. is a clinical-stage biotechnology company founded in 2014 by MIT researchers James Collins, PhD, and Tim Lu, MD, PhD, to develop Synthetic Biotics — a class of oral, GI-restricted medicines produced through precision genetic engineering of well-characterized probiotic bacteria. The company's proprietary platform combines molecular biology, microbial engineering, and physiology, supported by a library of synthetic biology components, metabolic gene circuitry, and regulatory genetic switches that enable engineered probiotics to consume or modify disease-specific metabolites within the gastrointestinal tract. The clinical pipeline includes labafenogene marselecobac (SYNB1934) for phenylketonuria under the Synpheny program, SYNB1353 for homocystinuria, SYNB8802 for enteric hyperoxaluria, SYNB2081 for gout, a preclinical cystinuria program, and an inflammatory bowel disease program developed in collaboration with Roche.

Synlogic is pre-revenue with no approved products, and operates as a publicly traded company on NASDAQ under ticker SYBX, headquartered in Cambridge, MA with a headcount of roughly 51–100 employees. The company's business model is structured around advancing drug candidates through clinical development toward regulatory approval, with the long-term monetization path based either on direct commercialization of approved biotherapeutics targeting rare metabolic diseases or on out-licensing rights to larger commercial partners. As of October 2023, the company completed a $21.0 million underwritten public offering intended to extend operating runway into the first half of 2025; operations have historically been funded through a mix of venture capital, public equity offerings, and strategic partnerships including a Roche IBD collaboration and an early-stage synthetic biology partnership with Ginkgo Bioworks.

Synlogic serves patients with rare metabolic diseases — including phenylketonuria, homocystinuria, enteric hyperoxaluria, gout, and cystinuria — where existing treatment options are limited by safety, efficacy, or tolerability concerns. The go-to-market approach, contingent on future approval, would rely on specialty rare-disease commercialization channels, healthcare provider engagement in metabolic disease centers, and patient advocacy partnerships. The discontinuation of the Synpheny-3 Phase 3 study in phenylketonuria materially reshaped the company's near-term trajectory and forced a strategic refocus toward earlier-stage pipeline assets and partnership-driven development.

Synlogic firmographics

Firmographics
Name
Synlogic
Legal name
Synlogic, Inc.
Website
https://synlogictx.com
Company type
Public
Founded year
2014
Operating status
Operating
Headcount range
51–100 employees
Short description
Synlogic is a clinical-stage biotechnology company developing Synthetic Biotics — orally administered, GI-restricted engineered probiotic medicines designed to consume or modify disease-specific metabolites. It targets patients with rare metabolic diseases including phenylketonuria, homocystinuria, enteric hyperoxaluria, gout, and cystinuria.
Ownership category
akta.pro rank

Synlogic industry classification

Industry
Product category
Biotherapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAFAD
Engineered Microbial Therapeutics (synthetic biology, gene circuits)
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Synthetic biotic medicines
  • Rare metabolic therapeutics
  • Engineered probiotic drugs
  • Oral biotherapeutic candidates
  • Clinical-stage biopharmaceuticals

Where Synlogic is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Synlogic business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Others, Marketing or Sales

Revenue model

  1. Biopharmaceutical Development: As a clinical-stage biotechnology company, Synlogic is focused on developing and commercializing its pipeline of Synthetic Biotics for rare metabolic diseases. The company is pre-revenue with no approved products yet, and is funded through public offerings and partnerships to advance clinical development toward regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Synlogic product offering

Product offering

Core offering

Synlogic develops Synthetic Biotics, a class of orally administered, GI-restricted biotherapeutic drug candidates created by precision genetic engineering of well-characterized probiotics. These drug candidates are designed to consume or modify disease-specific metabolites in the gastrointestinal tract to treat rare metabolic diseases including phenylketonuria (PKU), classical homocystinuria (HCU), enteric hyperoxaluria, gout, and cystinuria. The company operates a clinical-stage pipeline and is pre-revenue, advancing candidates through clinical trials toward regulatory approval.

Product overview

Synlogic is a clinical-stage biotechnology company developing Synthetic Biotics, a platform of living therapeutics created through precision genetic engineering of well-characterized probiotics. The company's portfolio includes multiple drug candidates: Labafenogene marselecobac (SYNB1934/Synpheny) for phenylketonuria (PKU), SYNB1353 for classical homocystinuria (HCU), SYNB8802 for enteric hyperoxaluria, SYNB2081 for gout, an undisclosed program for cystinuria, and an IBD program in collaboration with Roche. All candidates are designed as oral, GI-restricted medicines that consume or modify disease-specific metabolites.

Differentiator

Problem solved

Functional benefit

Brands

  • Synpheny: Brand name associated with Synlogic's phenylketonuria (PKU) treatment program and the drug candidate labafenogene marselecobac (SYNB1934).

Products and services

  • Labafenogene marselecobac (SYNB1934) / Synpheny An orally administered, GI-restricted Synthetic Biotic drug candidate designed to consume phenylalanine in the gastrointestinal tract, intended as a biotherapeutic for patients with phenylketonuria (PKU), an inherited metabolic disease where current treatment options are limited.
  • SYNB1353 A novel orally-administered, non-systemically absorbed Synthetic Biotic drug candidate designed to consume methionine in the gastrointestinal tract, thereby lowering homocysteine levels in patients with classical homocystinuria (HCU).
  • SYNB8802 A Synthetic Biotic drug candidate designed to consume dietary oxalate throughout the GI tract, being studied as a potential treatment for enteric hyperoxaluria, a chronic progressive disease characterized by high levels of urinary oxalate leading to recurrent kidney stones, kidney damage, and potential CKD/ESRD.
  • SYNB2081 A Synthetic Biotic drug candidate designed to lower uric acid as a potential treatment of gout, a complex form of inflammatory arthritis occurring when extra uric acid forms crystals in joints, causing intense pain, inflammation, and limited range of motion.
  • Undisclosed Cystinuria Program An early-stage Synthetic Biotic drug candidate program exploring the potential to reduce cystine in urine as a treatment for cystinuria, a genetic disease in which kidney stones consisting of cystine form and may recur or become lodged in the kidneys, ureters, or bladder.
  • IBD Program (Roche Collaboration) A research-stage Synthetic Biotic program under collaboration with Roche focused on the discovery of a novel oral biotherapeutic for the treatment of inflammatory bowel disease (IBD).

Quantifiable outcome

  • SYNB1934 demonstrated proof of concept in clinical studies for PKU treatment
  • +2 more outcomes

Companies that use Synlogic

Customer profile

Segments5 records

Ideal customer profiles1 record

Synlogic technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Synlogic partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • RochecoreStrategic or Co-development Partner · 1 June 2021In June 2021, Synlogic began a research collaboration with Roche focused on the discovery of a novel Synthetic Biotic for the treatment of inflammatory bowel disease (IBD). The partnership leverages Synlogic's synthetic biology expertise in combination with Roche's resources for drug discovery.
  • Ginkgo BioworkscoreStrategic or Co-development PartnerSynlogic partnered with Ginkgo Bioworks to develop additional preclinical assets, combining Synlogic's Synthetic Biotics approach with Ginkgo's Codebase and Foundry services. This partnership yielded SYNB1353 (for HCU) and SYNB2081 (for gout), the company's second drug candidate developed through this partnership.

Scale indicators1 record

Recent moves6 records

Expansion highlights4 records

Synlogic competitors and assessment

Company assessment

Emerging players

  • Tenaya Therapeutics: Clinical-stage gene therapy company with a PKU program (and other rare metabolic disease candidates). Comparable as a competing modality (gene therapy) targeting the same rare metabolic indications in Synlogic's pipeline.
  • Eligo Bioscience: Emerging engineered-microbiome company using synthetic biology to program resident bacteria (and phages) for precision therapeutic action. Comparable as a synthetic-biology-driven engineered microbe platform, though earlier-stage and more delivery-modality focused.
  • Federation Bio: Synthetic biology platform engineering defined and synthetic microbial communities for therapeutic use. Comparable through use of synthetic biology to engineer consortia of microbes to modulate disease-relevant metabolites in the GI tract.

Direct peers

  • Seres Therapeutics: Clinical-stage microbiome therapeutics company developing defined bacterial consortia for serious diseases (including SER-109 for recurrent C. difficile infection). Closely comparable to Synlogic in modality, stage, and reliance on regulatory designations and capital markets.
  • Novome Biotechnologies: Engineered microbial therapeutics company using genetically engineered gut bacteria to consume disease-driving metabolites (initial focus on hyperoxaluria). Highly comparable platform concept — engineered probiotics consuming metabolites — directly overlaps with SYNB8802's indication.
  • 4D Pharma: Clinical-stage microbiome therapeutics company with a pipeline of single-strain Live Biotherapeutic Products (LBPs) for cancer, respiratory, and gastrointestinal indications. Directly comparable modality and stage to Synlogic's Synthetic Biotics platform.
  • Vedanta Biosciences: Develops defined bacterial consortia and live biotherapeutics for immune-mediated diseases. Direct peer given shared focus on orally administered, GI-restricted bacterial therapeutics and similar mechanism-of-action leveraging the microbiome.
  • Evelo Biosciences: Clinical-stage company developing orally delivered microbial therapeutics for inflammatory diseases and oncology. Direct peer given shared GI-restricted single-strain therapeutic concept and rare/serious disease focus.

Broad incumbents

  • BioMarin Pharmaceutical: Established rare-disease leader with approved PKU treatments (Palynziq, pegvaliase). Not a microbiome peer, but a broad incumbent defining the commercial market and competitive landscape that Synlogic's discontinued PKU program would have entered.

Others

  • Ginkgo Bioworks: Synthetic biology platform company that is both a Synlogic collaboration partner (producing SYNB1353 and SYNB2081) and an adjacent infrastructure provider of engineered organism development services. Not a therapeutic competitor, but a strategic partner and ecosystem enabler.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Synlogic social profiles

Digital presence

Synlogic financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Synlogic leadership team

Management profile

Number of profiles

Profiles14 records

Synlogic funding detail

Funding detail

Funding overview

Funding rounds12 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Synlogic M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Synlogic

What does Synlogic do?

Synlogic develops Synthetic Biotics, a class of orally administered, GI-restricted biotherapeutic drug candidates created by precision genetic engineering of well-characterized probiotics. These drug candidates are designed to consume or modify disease-specific metabolites in the gastrointestinal tract to treat rare metabolic diseases including phenylketonuria (PKU), classical homocystinuria (HCU), enteric hyperoxaluria, gout, and cystinuria. The company operates a clinical-stage pipeline and is pre-revenue, advancing candidates through clinical trials toward regulatory approval.

Is Synlogic a public or private company?

Synlogic is a public company. It is classified as public and is currently operating.

When was Synlogic founded?

Synlogic was founded in 2014. It employs 51 to 100 people.

Where is Synlogic based?

Synlogic is headquartered in Cambridge, United States, in the North America region.

How does Synlogic make money?

One revenue line is on record: biopharmaceutical Development.

Who are Synlogic's main competitors?

Emerging players on record are Tenaya Therapeutics, Eligo Bioscience and Federation Bio. Direct peers are Seres Therapeutics, Novome Biotechnologies, 4D Pharma, Vedanta Biosciences and Evelo Biosciences. BioMarin Pharmaceutical is listed as a broad incumbent. Ginkgo Bioworks is listed as an others.

Does Synlogic have an API?

No public API is recorded for Synlogic.

What industry is Synlogic in?

Synlogic's product category is Biotherapeutics. Its primary akta.pro industry code is HLAAAFAD, Engineered Microbial Therapeutics (synthetic biology, gene circuits), with a secondary code of HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Ticker ReportContrasting Synlogic (NASDAQ:SYBX) and Allarity Therapeutics (NASDAQ:ALLR)Synlogic and Allarity Therapeutics are compared on valuation, earnings, and analyst ratings. Allarity has higher revenue and earnings, but Synlogic trades at a lower P/E ratio. Analysts rate Allarity more favorably with a consensus price target of $10.25, implying 935% upside.American Banking and Market NewsAllarity Therapeutics (NASDAQ:ALLR) versus Synlogic (NASDAQ:SYBX) Head to Head ContrastAllarity Therapeutics and Synlogic are compared on valuation, analyst ratings, and earnings. Allarity has higher revenue ($345M vs $8M) and a stronger consensus rating with a $10.25 target price, while Synlogic trades at a lower P/E ratio. Synlogic beats Allarity on 7 of 13 factors.American Banking and Market NewsHead-To-Head Survey: Bicycle Therapeutics (NASDAQ:BCYC) & Synlogic (NASDAQ:SYBX)Bicycle Therapeutics and Synlogic are compared on profitability, risk, and analyst ratings. Bicycle Therapeutics beats Synlogic on 8 of 14 factors, with a consensus target price of $13.86 and 253% upside. Analysts favor Bicycle Therapeutics over Synlogic.Markets DailyIonis Pharmaceuticals (NASDAQ:IONS) versus Synlogic (NASDAQ:SYBX) Critical SurveyIonis Pharmaceuticals and Synlogic are compared on institutional ownership, volatility, profitability, and analyst ratings. Ionis has higher institutional ownership (93.9% vs 63.4%) and a stronger consensus rating with a $89.20 price target, while Synlogic trades at a lower P/E ratio.Markets DailyAnalyzing Synlogic (NASDAQ:SYBX) & Inovio Pharmaceuticals (NASDAQ:INO)Synlogic and Inovio Pharmaceuticals are compared on institutional ownership, valuation, and analyst ratings. Inovio has a stronger consensus rating and a $3.17 target price implying 168.36% upside, while Synlogic trades at a lower P/E ratio. Inovio beats Synlogic on 8 of 14 factors.Markets DailyHead to Head Analysis: Kyntra Bio (NASDAQ:KYNB) & Synlogic (NASDAQ:SYBX)Kyntra Bio outperforms Synlogic on 13 of 15 factors, including higher revenue and earnings. Analysts rate Kyntra Bio more favorably with a consensus price target of $37.25, implying 426.87% upside. Kyntra Bio also has stronger institutional ownership at 72.7% versus Synlogic's 63.4%.Morningstar$HAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of the Merger - BWMN, SUNS, DV and SYBXMonteverde & Associates PC announced investigations into four mergers: Bowman Consulting's sale to Bernhard Capital Partners, Blue Sunrise Realty's merger with Southern Realty, DoubleVerify's sale to Nielsen, and Synlogic's merger with Caldera. Deal terms include $43 per Bowman share, $13.60 per DoubleVerify share, and Sunrise shareholders expected to own 62% of the combined company.FinancialContent Business PageBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Varex Imaging Corporation (Nasdaq – VREX), Synlogic, Inc. (OTC – SYBX), Bowman Consulting Group Ltd. (Nasdaq –Brodsky & Smith, a litigation law firm, notified investors of shareholder investigations into four companies under review for alleged breaches of fiduciary duty by their boards over proposed mergers. The companies are Varex Imaging, Synlogic, Bowman Consulting Group and Nathan's Famous, with deal values of roughly $1.1 billion, $450 million, $1.0 billion and $450 million respectively.Ticker ReportAnalyzing Synlogic (NASDAQ:SYBX) & Generate Biomedicines (NASDAQ:GENB)MarketBeat compares the investment potential of healthcare companies Generate Biomedicines and Synlogic based on financial metrics, analyst recommendations, and profitability. The analysis highlights that Generate Biomedicines holds a stronger consensus rating with higher probable upside compared to Synlogic, which is currently trading at a lower price-to-earnings ratio.FinancialContent Business PageSYBX Stock Alert: Halper Sadeh LLC is Investigating Whether Synlogic, Inc. is Obtaining a Fair Price for its ShareholdersHalper Sadeh LLC, an investor rights law firm, is investigating the proposed merger between Synlogic, Inc. and Caldera Therapeutics, Inc. to determine if the deal offers fair value and was conducted without conflicts of interest. The investigation concerns whether Synlogic's directors violated securities laws or fiduciary duties, potentially seeking better terms for shareholders.